DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine
DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine
复制标题
DOI：
10.1016/s0264-410x(02)00193-7
复制
发表时间：
2002-06-21
期刊：
影响因子：
5.5
通讯作者：
Beck, A
中科院分区：
文献类型：
--
作者：
Klinguer-Hamour, C;Libon, C;Beck, A
人呼吸道合胞病毒（hRSV）是婴儿和老年人呼吸道感染的最常见原因之一。以前尝试给儿童接种抗RSV疫苗失败，并且异常Th 2型免疫应答的诱导被证明可诱导部分以嗜酸性粒细胞增多为特征的严重至致死性肺部疾病。BBG 2Na是一种很有前途的人RSV亚单位疫苗候选者，它成功地通过了与Adu-Phos（R）联合的成人II期临床试验。然而，该制剂不是最适合用于儿童的，因为已知铝盐诱导基于Th 2的免疫应答。在这项研究中，我们描述了BBG 2Na在二甲基双十八烷基溴化铵（DDA）中的有效且安全的佐剂制剂，其在BALB/c小鼠中诱导混合Th 1/Th 2免疫应答。此外，当在DDA或明矾中配制时，BBG 2Na在小鼠和棉鼠中显示出相同的针对RSV攻击的保护功效。(C)2002爱思唯尔科技有限公司版权所有。
Human respiratory syncytial virus (hRSV) is one of the most common causes of respiratory infection in infants and the elderly. Previous attempts to vaccinate children against RSV failed and the induction of an aberrant Th2-type immune response was shown to induce severe to fatal pulmonary disease characterised in part by eosinophilia. BBG2Na is a promising human RSV subunit vaccine candidate which successfully passed phase II clinical trials in adults in association with Adju-Phos(R). However, this formulation is not the most suitable for use in children since aluminium salts are known to induce a Th2-based immune response. In this study, we describe a potent and safe adjuvant formulation for BBG2Na in dimethyldioctadecylammonium bromide (DDA) that induces a mixed Th1/Th2 immune response in BALB/c mice. Furthermore, BBG2Na showed the same protective efficacy against RSV challenge when formulated either in DDA or in alum in mice and cotton rats. (C) 2002 Elsevier Science Ltd. All rights reserved.